Showing 1 - 10 of 18,818
Three months into the COVID-19 outbreak caused by a novel strain of coronavirus (SARS-CoV-2), the world is still in search of an effective therapeutic drug. Experimental drugs developed for other infections, such as Gilead's remdesivir, have been repurposed with unclear success. A recent small...
Persistent link: https://www.econbiz.de/10012837598
We have examined all the US patents (444) issued to homegrown Indian pharma and pharma biotech firms. Most (425, 95%) patents are pharma patents not biotech (19). Also, only 11 patents have been cited ten times or more. This data provides one snapshot of the biotech industry in India today. It...
Persistent link: https://www.econbiz.de/10014129813
In August of 1997, the Food and Drug Administration (FDA) set new less restrictive guidelines for direct-to-consumer (DTC) advertisements by pharmaceutical companies. I examine the common stock price reaction of pharmaceutical companies following the announcement of new FDA guidelines on...
Persistent link: https://www.econbiz.de/10014066450
The Belgian pharmaceutical sector has been accorded a leading role in the attainment of the R&D investment targets which the EU Member States set themselves as part of the Lisbon strategy. To gain a better insight into that sector's research activities, the NBB conducted an ad hoc survey in...
Persistent link: https://www.econbiz.de/10011618278
To meet the requirements of global competition, the European Union (EU) places particular emphasis on the development of knowledge‑intensive, innovative industries. The pharmaceutical industry, as a high‑tech manufacturing subsection, has a long tradition in Europe. However, the distribution...
Persistent link: https://www.econbiz.de/10012665037
with newly introduced generics of the original drug. If instead, the reformulated drug was to be introduced well before the …
Persistent link: https://www.econbiz.de/10014135034
This paper analyses how governments can introduce more competition in the pharmaceutical sector. Considering it involves harmonizing issues such as incentives to innovate and perform research and development (R&D), Intellectual Property (IP) rights, healthcare policy and public budget concerns,...
Persistent link: https://www.econbiz.de/10014130511
New information technologies enable individuals in disparate locations to conduct cutting-edge research, to move that research into the development and testing of new medicines, to manufacture high-quality products, and to move those products to patients around the world. Conceptually, the world...
Persistent link: https://www.econbiz.de/10014041752
In this paper we use published information to provide analyze the economic value of Direct to Consumer (DTC) advertising. We use information on: the effect of DTC in generating patient visits; the effect of patient visits and mentions of a drug in generating prescriptions; and the effect of...
Persistent link: https://www.econbiz.de/10014047829
The role of the patent system in promoting pharmaceutical innovation is widely seen as a tremendous success story. This view overlooks a serious shortcoming in the drug patent system: the standards by which drugs are deemed unpatentable under the novelty and non-obviousness requirement bear...
Persistent link: https://www.econbiz.de/10014218419